Ms. Morales-Rivera’s recent client representations include the following:
General Corporate Counseling and Significant Transactions
- Accent Therapeutics $63.0 million Series B financing
- Akero Therapeutics in connection with:
- its $65 million Series A financing
- its $70 million Series B financing
- its $105.8 million initial public offering
- its $216.4 million follow-on public offering
- Allovir in its $120 million Series B financing
- Aptinyx in connection with:
- its $65 million Series A financing
- its $70 million Series B financing
- its $117.8 million initial public offering
- Cullinan Oncology in its $98.5 million Series B Financing
- ElevateBio in connection with:
- its $150 million Series A financing
- its $193 million Series B financing
- Exosome Diagnostics in connection with:
- its $30 million Series C financing
- its sale to Bio-Techne Corporation
- Forma Therapeutics in connection with:
- its $100 million Series D financing
- its $319.3 million initial public offering
- Kymera Therapeutics in connection with:
- its $30 million Series A financing
- its $65 million Series B financing
- its research and development collaboration with Vertex Pharmaceuticals
- its $200 million initial public offering
- MoMa Therapeutics in its $86.0 million Series A financing
- Neon Therapeutics in connection with:
- its $106 million Series B financing
- its $100 million initial public offering
- its $97 million sale to BioNTech
- Nimbus Therapeutics in connection with:
- the $1.2 billion sale of its ACC inhibitor program to Gilead Bioscience
- its multi-target strategic alliance with Celgene Corporation in immunology
- its $65 million Series 2018 preferred stock financing
- its $43 million Series B financing
- Quench Bio in its $50 million Series A financing
- Relay Therapeutics in connection with:
- its $63 million Series B financing
- its $400 million Series C financing
- its $460 million initial public offering
- ROME Therapeutics in its $50 million Series A financing
- SmileDirectClub in its $380 million financing
- Tango Therapeutics in connection with:
- its $55 million Series A financing
- its $60 million Series B financing
- its $40 million equity financing
Public Company Representation and Capital Markets Transactions
- Intellia Therapeutics in connection with:
- its $150 million follow-on offering
- its $115 million follow-on offering
- its expanded licensing agreement with Regeneron Pharmaceuticals
- Sage Therapeutics in its $575 million and $345 million follow-on offering
- Repligen Corp. in connection with:
- its acquisition of TangenX Technology Corporation
- its acquisition of Spectrum, Inc.
- its $138 million follow-on offering
- resTORbio in connection with:
- its $97.8 million initial public offering
- its $50 million follow-on offering
Professional Experience
While attending law school, Ms. Morales-Rivera interned for the Honorable Juan R. Torruella of the First Circuit Court of Appeals.
Ms. Morales-Rivera is a member of the Boston and American Bar Associations as well as the Hispanic National Bar Association.